Disease · MONDO_0004781
Comparisons in its trials48
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 48
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding | 89 of 1,800 | 149 of 1,802 | 3,602 | NCT00433966 | Trial comparisons |
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events | 379 of 1,800 | 377 of 1,802 | 3,602 | NCT00433966 | Trial comparisons |
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events | 98 of 1,800 | 99 of 1,802 | 3,602 | NCT00433966 | Trial comparisons |
| Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events | 166 of 1,800 | 218 of 1,802 | 3,602 | NCT00433966 | Trial comparisons |
| Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Ischemic Target Lesion Revascularization | 98 of 2,257 | 54 of 749 | 3,006 | NCT00433966 | Trial comparisons |
| Stent Arm - Paclitaxel-Eluting Stent vs Stent Arm - Bare Metal Stent: Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis | 181 of 2,257 | 59 of 749 | 3,006 | NCT00433966 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke | 117 of 949 | 135 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Shock | 59 of 949 | 73 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Ischaemic Stroke | 6 of 949 | 3 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Congestive Heart Failure (CHF) | 57 of 949 | 72 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Total Stroke (All Types) | 15 of 949 | 5 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Cardiogenic Shock | 41 of 949 | 56 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions | 61 of 949 | 45 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Recurrent Myocardial Infarction (Reinfarction) | 23 of 949 | 21 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Death and Non-fatal Stroke | 50 of 949 | 43 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Serious Resuscitated Ventricular Fibrillation | 32 of 949 | 38 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Total Disabling Stroke | 2 of 949 | 0 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Intracranial Haemorrhage | 9 of 949 | 2 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With All Cause Mortality | 43 of 949 | 42 of 948 | 1,897 | NCT00623623 | Trial comparisons |
| Tenecteplase (Group A) vs Primary PCI (Group B): Number of Patients With Total Non-intracranial Bleeds | 267 of 949 | 236 of 948 | 1,897 | NCT00623623 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004781/comparisons